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IL-1β–dependent extravasation of preexisting lungrestricted autoantibodies during lung transplantation
activates complement and mediates primary
graft dysfunction
Wenbin Yang,1 Emily Jeong Cerier,1 Félix L. Núñez-Santana,1 Qiang Wu,1 Yuanqing Yan,1 Chitaru Kurihara,1 Xianpeng Liu,1
Anjana Yeldandi,2 Nigar Khurram,2 Diego Avella-Patino,1 Haiying Sun,1 G.R. Scott Budinger,3 Daniel Kreisel,4
Thalachallour Mohanakumar,5 Emilia Lecuona,1 and Ankit Bharat1,3
Division of Thoracic Surgery, 2Department of Pathology, and 3Pulmonary and Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 4Departments of Surgery,
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Pathology & Immunology, Washington University, St. Louis, Missouri, USA. 5Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona, USA.

Preexisting lung-restricted autoantibodies (LRAs) are associated with a higher incidence of primary graft dysfunction
(PGD), although it remains unclear whether LRAs can drive its pathogenesis. In syngeneic murine left lung transplant
recipients, preexisting LRAs worsened graft dysfunction, which was evident by impaired gas exchange, increased
pulmonary edema, and activation of damage-associated pathways in lung epithelial cells. LRA-mediated injury was
distinct from ischemia-reperfusion injury since deletion of donor nonclassical monocytes and host neutrophils could
not prevent graft dysfunction in LRA-pretreated recipients. Whole LRA IgG molecules were necessary for lung injury,
which was mediated by the classical and alternative complement pathways and reversed by complement inhibition.
However, deletion of Fc receptors in donor macrophages or mannose-binding lectin in recipient mice failed to
rescue lung function. LRA-mediated injury was localized to the transplanted lung and dependent on IL-1β–mediated
permeabilization of pulmonary vascular endothelium, which allowed extravasation of antibodies. Genetic deletion
or pharmacological inhibition of IL-1R in the donor lungs prevented LRA-induced graft injury. In humans, preexisting
LRAs were an independent risk factor for severe PGD and could be treated with plasmapheresis and complement
blockade. We conclude that preexisting LRAs can compound ischemia-reperfusion injury to worsen PGD for which
complement inhibition may be effective.

Introduction

Primary graft dysfunction (PGD) affects over 50% of recipients
following lung transplantation and has emerged as the principal
risk factor for both short-term mortality as well as long-term graft
loss from chronic rejection (1–4). Current empiric therapies to treat
PGD are largely ineffective and have the attendant risks of immunosuppression. While ischemia-reperfusion injury remains its predominant cause, the highly variable incidence of PGD suggests
additional etiologies for its pathogenesis. A significant percentage of patients undergoing lung transplantation have preexisting
immunoglobulin G (subtype IgG2) autoantibodies against lungrestricted self-antigens collagen type V (COLV) and K-α1 tubulin
(KAT) (5, 6). The presence of these lung-restricted autoantibodies
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(LRAs) in the recipients is associated with an increased risk of PGD
following both human (6) and murine (5, 7–9) lung transplantation.
However, the molecular events by which LRAs promote PGD and
their relationship to transplant-inherent ischemia-reperfusion injury remain unknown. Understanding of the pathogenesis of PGD in
recipients with underlying LRAs will enable the development of
selective therapies to improve posttransplant outcomes.
Investigators have suggested a mechanism to explain the
production of LRAs in patients with chronic lung diseases (10).
The deletion of self-reactive T lymphocytes against lung selfantigens by the thymus is incomplete, and escaped self-reactive T
lymphocytes are dynamically suppressed through peripheral regulatory T cells (11). Depletion of regulatory T cells in response to
environmental challenge promotes the expansion of self-reactive
T lymphocytes and development of LRAs (10). The lung self-antigens are nonpolymorphic and are normally sequestered from the
immune system, as they serve as scaffolds for the structural proteins (12). However, during transplantation the self-antigens might
be revealed as the structural proteins are cleaved, for example
through the activation of matrix metalloproteinases, allowing the
preexisting LRAs to bind and promote downstream immune activation (13). These self-antigens are extravascular but the increased
1
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vascular permeability that occurs during ischemia-reperfusion
injury could allow extravasation of the LRAs (14). We found
that LRAs compound ischemia-reperfusion injury through the
activation of complement, resulting in severe PGD. Our findings
reveal pathways through which LRAs mediate lung allograft injury
that can be targeted clinically.

Results

Intact LRAs promote primary graft dysfunction. LRAs belong to the
IgG family of immunoglobulins (5, 6), which are composed of Fc
and F(ab′)2 fragments. The F(ab′)2 fragment exhibits sequence
variability and recognizes antigens, while the Fc fragment provides
interaction sites for effector molecules such as complement and
Fcγ receptors (FcγRs) (15). However, F(ab′)2 can also independently
interact with FcγRs to mediate immunological effects (16). To determine the pathogenicity of LRAs, we injected IgG isotype, LRAs, or
the cleaved F(ab′)2 fragment into recipient mice prior to transplantation. As expected, ischemia-reperfusion injury was inherent to this
model and experienced by all animals, evident by decreased lung
graft function in the recipients of IgG isotype control compared with
naive lung (isotype PaO2/FiO2 ratio: 452.3 ± 63 mmHg; naive PaO2/
FiO2 ratio: 621.9 ± 32 mmHg; P < 0.0001). Recipients injected with
whole LRA IgG molecules showed significant worsening in lung
graft function (PaO2/FiO2 ratio: 104.2 ± 41 mmHg; Figure 1A) as
well as increased pulmonary edema (Figure 1B), while those injected with F(ab′)2 fragments demonstrated expected levels of lung
graft dysfunction resulting from ischemia-reperfusion injury (Figure 1, A and B). There was increased neutrophil infiltration determined by flow cytometry in mice with whole LRA molecules (Figure
1C) along with capillaritis and inflammatory cells found on histological analysis (Figure 1, D and E). In addition, 2-photon imaging
(Figure 1F, Supplemental Figure 1, and Supplemental Videos 1 and
2; supplemental material available online with this article; https://
doi.org/10.1172/JCI157975DS1) showed increased LRA deposition
in the allograft after lung transplantation. Unbiased transcriptomic
analysis using single-cell RNA sequencing (RNA-seq) (Supplemental Figure 2) revealed activation of several damage-associated pathways (Figure 2A), including oxidative stress (reflected as increased
expression of antioxidant proteins; Figure 2B) and complement
(increased C3 expression; Figure 2C) in the epithelial cells during
LRA-mediated lung graft injury.
LRAs activate classical and alternative complement pathways
to mediate lung graft injury. Since F(ab′)2 could not induce PGD,
we reasoned that the Fc region was necessary for the pathogenic
effects of LRAs. Accordingly, we investigated whether LRA-mediated lung injury occurred through FcγR or complement activation
(17). Donor lungs from Fcrγ–/– mice transplanted into syngeneic
recipients pretreated with LRAs experienced severe lung injury,
similar to those from wild-type donor lungs (Figure 3, A and B). We
used these mice, as donors and not recipients as the predominant
macrophages in the donor lungs at 24 hours are of donor origin
(18). This led us to further hypothesize that LRAs activate complement to induce lung graft dysfunction.
We first studied component C3, as it acts as a point of convergence for the different complement pathways. Indeed, C3 levels
were elevated in the BAL of grafts from wild-type or Fcrγ–/– recipients pretreated with LRAs but not in those that received isotype
2

control (Figure 3C). Moreover, genetic deletion of C3 in recipient
mice resulted in nearly complete protection against LRA-induced
lung graft dysfunction (Figure 3, D and E). Next, we determined
the specific complement pathway activated by LRAs using genetic deletion and pharmacological inhibition. We transplanted
wild-type donor lungs into C1q –/– (classical pathway), Mbl–/– (mannose-binding lectin, lectin pathway), or FBI-treated (factor B
inhibitor, alternative pathway) recipients. Each of these recipients also received LRAs or isotype control antibodies prior to the
transplant. Preexisting LRAs induced severe lung graft dysfunction in Mbl–/– mice, while the C1q –/– and FBI-treated recipients were
protected (Figure 4, B and C). Furthermore, treatment of recipient mice with a pharmacological C1 inhibitor (C1INH) resulted
in protection of the transplanted lungs from LRA-induced injury
as well as associated increases in neutrophil recruitment (Figure
4, B and C). Immunohistochemistry confirmed complement C4d
deposition, a marker of classical pathway activation, in the lung
grafts of LRA-treated recipients (Figure 4D). All 3 complement
pathways can induce the formation of the membrane attack complex (MAC). MAC assembly requires the sequential and irreversible association of complement proteins C5b, C6, C7, C8, and C9
(19, 20). Immunohistochemical analysis showed MAC deposition
in grafts from LRA-recipient mice (Figure 4E). Inhibiting activation of C5, and thus the generation of C5a and MAC, has shown
great therapeutic benefit in complement-driven inflammatory
diseases (21). Hence, we inhibited C5 by using a C5-blocking
antibody and found prevention of LRA-induced graft dysfunction
(Figure 4, B and C). Together, these data suggested that LRAs
activate both the classical and alternative complement pathways
to mediate lung graft injury.
LRA-induced lung dysfunction is complementary but distinct
from ischemia-reperfusion injury. We have previously reported that
ischemia-reperfusion injury is inherent to lung transplantation
and is dependent on the influx of host neutrophils into the transplanted lung through retained donor-origin pulmonary intravascular nonclassical monocytes (22, 23). To determine whether
LRAs can independently induce lung graft dysfunction, we used
lungs from murine Nur77–/– (Nr4a1–/–) donors, which lack nonclassical monocytes and do not experience neutrophil-mediated ischemia-reperfusion injury, as we previously reported (23). We found
that transplantation of nonclassical monocyte–deficient donor
lungs into LRA-pretreated recipients resulted in severe lung graft
dysfunction (Figure 5, B and C). Nevertheless, it was intriguing
that lung grafts in the presence of donor nonclassical monocytes
revealed increased neutrophil influx when LRAs were present in
the recipients prior to transplantation (Figure 1C). To determine
whether neutrophils contributed to the pathogenesis of LRAinduced lung graft injury, we depleted host neutrophils using antiLy6G antibodies, as previously described (18) (Supplemental Figure 3). Neutrophil depletion in mice with preexisting LRAs did not
prevent posttransplant lung injury, as measured by pulmonary
edema (Figure 5D and Supplemental Figure 3) and PaO2/FiO2
ratio (Figure 5E). Comparison of lung function between isotype
and LRA (PaO2/FiO2 [mmHg] isotype: 372.6 ± 82 [n = 3]; LRA:
93.7 ± 23 [n = 4]; P < 0.001) and isotype-IgG-control and LRAIgG-Ly6G (PaO2/FiO2 [mmHg] isotype: 434 ± 49 [n = 3]; LRA:
190 ± 44 [n = 3]; P < 0.01) showed no protection in graft injury.
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We first treated primary pulmonary endothelial cells in vitro with exogenous IL-1β
(50 ng/mL) and found that it significantly
increased endothelial permeability and the
passage of LRAs through the barrier (Figure
6A). We then transplanted wild-type, IL-1R
antagonist–treated (IL-1RA–treated), or
Il1r–/– lungs into wild-type LRA-treated syngeneic recipients. Donor lungs treated with
IL-1RA or those from Il1r–/– mice showed
preserved lung graft function (Figure 6C),
decreased neutrophil influx (Figure 6D),
and no C4d deposition (Figure 6E). There
was no difference in graft function among
the isotype and LRA group treated with
IL-1RA or when Il1r–/– donor lung was used
(PaO2/FiO2 [mmHg] IL-1RA–isotype: 515.7
± 24 [n = 3]; Il1r–/–-isotype: 412 ± 141 [n =
3]; IL-1RA–LRA: 368 ± 41 [n = 3]; Il1r–/–LRA: 404 ± 154 [n = 4]). To further investigate the role of IL-1β, we injected wildtype mice with IL-1β or PBS, 8 hours prior
to injecting LRAs, and determined LRA
deposition and complement activation. We
found retention of LRAs (Figure 6F) with
IL-1β pretreatment in naive lungs, similar
to lung allografts (Supplemental Figure 1),
but it was not associated with C4d depoFigure 1. Preexisting whole lung-restricted antibodies (LRAs) against self-antigens induce primary
sition (Figure 6G), indicating that IL-1β is
graft dysfunction after syngeneic murine lung transplantation. Recipient mice received 150 μg each
necessary for the extravasation of LRAs
(i.v.) of isotype control, LRAs (anti–collagen type V plus anti–K-α1 tubulin), or LRA F(ab′)2 portion, 24
but not sufficient to trigger LRA-mediated
hours before and 1 hour after lung transplantation. (A) Twenty-four hours after transplantation, arterial
complement activation.
blood oxygenation was analyzed after clamping the right hilum (n = 3–4). Lungs were also harvested for
assessment of (B) pulmonary edema (n = 3–5) and (C) neutrophils (live CD45+SiglecF–CD11b+Ly6G+) (n = 3).
Preexisting LRAs are an independent
(D) Histology showing capillaritis and alveolar edema in mice treated with LRAs but not isotype control
risk of human PGD. We prospectively
antibodies. Scale bar: 20 μm. (E) Inflammatory cells (both polymorpho- and mononuclear) were counted
analyzed LRAs in 56 patients undergoin 10 high-power fields (×40) and averaged for each group. (F) Pictures from 2-photon microscopy showing
ing lung transplantation. The cumulative
LRA (magenta) deposition. Scale bar: 50 μm. Data are presented as mean ± SD. PaO2/FiO2, arterial oxygen
prevalence of detectable preexisting antipressure. Graphs in A–C were analyzed by 1-way ANOVA followed by Tukey’s post hoc test. Graph in E was
analyzed by unpaired, 2-tailed Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
COLV and anti-KAT antibodies was 14.3%
in this cohort. The demographic profile
of the patients is presented in Table 1. In
the study cohort, 4 (7.1%) patients developed grade 3 PGD: 2 (25%) with and 2 (4.5%) without preexisting
These data indicated that LRA-induced lung graft dysfunction
LRAs (P = 0.09; Supplemental Table 1). Logistic regression modis complementary to neutrophil-mediated ischemia-reperfusion
eling revealed that only preexisting LRAs were an independent
injury and predominantly occurs through complement activation.
predictor of grade 3 PGD after lung transplantation (SuppleIL-1β is necessary for vascular endothelial permeabilization and
mental Table 2 and Table 2). In patients with preexisting LRAs, a
extravasation of LRAs. The native lung of the LRA-treated recipients
postreperfusion biopsy was performed at 60 minutes. Both patients
showed no histological evidence of injury. Additionally, there was no
with preexisting LRAs who developed grade 3 PGD revealed hisincrease in neutrophils in the native lungs of LRA-treated recipients
tological features reminiscent of acute antibody-mediated rejec(neutrophils/mg lung isotype: 1685 ± 760; LRA: 1445 ± 1008). Lungtion with complement (C4d) deposition (Supplemental Figure 4).
restricted antigens are present in the interstitial space (12) and, hence,
These patients were treated with the complement inhibitor eculiwe next hypothesized that extravasation of LRAs into the interstitial
zumab, along with plasma exchange, and experienced resolution
space, which might uniquely occur in the transplanted lung graft,
of lung allograft dysfunction (Supplemental Figure 4).
was necessary for the activation of complement. We have previously shown that IL-1β can increase pulmonary vascular permeability and allow cellular extravasation (24). Hence, we tested whether
Discussion
release of IL-1β within the transplanted lung was necessary to permit
Neutrophil-mediated ischemia-reperfusion injury is suggested to
extravasation of circulating LRAs and gain access to the antigens.
be the predominant cause of PGD (1, 25). However, it is evident
J Clin Invest. 2022;132(20):e157975 https://doi.org/10.1172/JCI157975
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with complement deposition
in lung grafts, whether they
can activate complement
remains unclear (26). The
classical complement pathway depends on the binding
of C1q protein to antibody
attached to antigen, activating C1r and C1s, which cleave
C4 and C2. The lectin complement pathway is activated
when mannose-binding lectin
(MBL) interacts with carbohydrate motifs on pathogens.
This results in the activation
of MBL-associated proteases,
which also cleave C4 and C2.
Hence, both classical and lectin pathways form C3 convertase after cleaving C4 and C2
and initiate the downstream
proteins. In contrast, the alternative pathway is activated
by spontaneous hydrolysis of
C3, in the presence of Factors
B and D, leading to the evenFigure 2. Differential expression analysis of single-cell RNA-seq data from isotype- or LRA-treated murine
tual formation of the C3 and
allograft after lung transplantation within epithelial cells. (A) Functional enrichment analysis with GO Biological
C5 convertase. In the alternaProcesses was performed with the significantly upregulated genes in epithelial cells from LRA-treated compared
tive pathway, properdin plays
with isotype-treated murine lung allograft. (B and C) Violin plots of expression for select genes significantly upregan important role as it stabiulated in epithelial cells from LRA-treated compared with isotype-treated murine lung allograft.
lizes the protein. All 3 pathways culminate in the formation of effector compounds
(29). Since deletion of MBL did not alter the graft injury in LRAthat the syndrome of PGD includes etiologies other than ischpretreated mice, we conclude that the lectin pathway is not
emia-reperfusion injury. Preexisting LRAs are present in a signifinvolved. However, C1q and Factor B inhibition prevented LRA-inicant proportion of patients undergoing lung transplantation and
duced lung graft dysfunction, suggesting a role for classical and
are strongly associated with an increased risk of PGD (6). Studies
alternative complement pathways in this model. Our findings
in which right and left lungs from single donors were transplanted
also explain the immunological mechanisms behind the reportinto different recipients with or without autoantibodies have fured detection of complement proteins in patients with PGD (30).
ther suggested their role in the pathogenesis of PGD (26). HowHowever, the differences with our study might be related to our
ever, the mechanistic pathways through which LRAs contribute
focus on LRAs, where IgG glycosylation might have a less relevant
to PGD remain unclear. Importantly, the relationship between
role than C1q binding to the Fc portion of IgG. It is also noteworthy
LRA-induced graft dysfunction and classical pathways that conthat while LRAs might activate host cellular immunity and phagotribute to transplant-inherent ischemia-reperfusion injury remains
cytosis by binding FcγRs on target cells, those did not contribute
unknown. Our current study identifies clinically actionable pathto the LRA-mediated graft dysfunction since Fcrγ–/– donor lungs
ways through which preexisting LRAs add to ischemia-reperfusion
injury to worsen PGD. Given that the LRAs caused severe lung
experienced similar injury to that of wild-type grafts. Our findings
graft injury even when neutrophil-mediated ischemia-reperfusion
have immediate clinical implications since complement inhibitors
injury was mitigated, we postulate that treatment of LRA-induced
are FDA approved and commercially available.
lung graft injury could result in amelioration of PGD and improveUnlike histocompatibility antigens, the cognate self-antigens for
ment in posttransplant outcomes.
the LRAs are nonpolymorphic and conserved (31). Ischemia-reperfuThe complement system is an essential part of the innate
sion can reveal epitopes of self-antigens that typically serve as strucimmune system that has been associated with ischemia-repertural lung proteins (32), possibly through the activation of matrix
fusion injury and transplantation (27). Indeed, PGD has been
metalloproteinases (5, 33–35). Exposure of the self-antigens can then
associated with complement deposition, although whether these
promote the binding with LRAs (7). We have also previously shown
transplant recipients had preexisting LRAs is unknown (28).
that donor-origin nonclassical monocytes retained in the pulmonary
Additionally, while preexisting LRAs have also been associated
vasculature initiate the pathogenesis of ischemia-reperfusion injury
4
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the lung self-antigens, COLV and KAT, are normally sequestered, typically forming scaffolds
for larger structural proteins such as collagen
type I (36). As such, the immunogenic epitopes
of these self-antigens are not accessible to the
immune system or the extravasated antibodies
in resting mice. When we administered IL-1β to
permeabilize the vascular endothelium, the circulating LRAs extravasated into the interstitium
but were unable to activate complement, as they
did not bind to their cognate antigen. In contrast, during ischemia-reperfusion injury, there
is activation of catalytic enzymes such as matrix
metalloproteinases (37), which can cleave
these self-antigens, enabling the formation of
LRA-antigen immune complex and activation
of complement. Hence, these findings suggest
the need for both IL-1β and ischemia-reperfusion injury to activate the complement and
induce C4d deposition (38, 39). Together,
these data suggest that while the mechanisms
of LRA-induced injury are distinct from ischemia-reperfusion injury, the molecular and
immunological changes during ischemia-reperfusion are necessary for the pathogenicity
Figure 3. LRAs activate complement pathway to mediate lung graft injury. (A) WT or Fcrγ–/–
of LRAs. Our findings also suggest inhibition
recipients received 150 μg each (i.v.) of isotype control or LRAs (anti–collagen type V plus anti–K-α1
of IL-1β or the IL-1β receptor as a therapy to
tubulin) 24 hours before and 1 hour after lung transplantation. Arterial blood oxygenation was
prevent
both ischemia-reperfusion and LRAanalyzed after clamping the right hilum (n = 4). (B) Lungs treated as in A were also harvested for
associated injury. Notably, canakinumab and
neutrophil quantification (live CD45+SiglecF–CD11b+Ly6G+) (n = 3). (C) WT or Fcrγ–/– recipient mice
were treated as in A. Twenty-four hours after transplantation, bronchoalveolar lavage fluid (BALF)
anakinra, agents that block IL-1β and the IL-1β
was obtained and C3 concentration measured by ELISA (n = 3–6). (D) WT or C3–/– recipient mice
receptor, respectively, have relatively benign
were treated as in A. Arterial blood oxygenation was analyzed after clamping the right hilum (n =
short-term safety profiles and have received
3). (E) Quantification of neutrophil recruitment into lungs in mice treated as in A (neutrophil gatFDA approval for other indications.
+
–
+
+
ing: live CD45 SiglecF CD11b Ly6G ) (n = 3–5). Data are presented as mean ± SD. PaO2/FiO2, arterial
Our study has limitations. First, we canoxygen pressure. Graphs were analyzed by 1-way ANOVA followed by Tukey’s post hoc test. *P <
0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; NS, not significant.
not determine whether prophylaxis or desensitization against LRAs is beneficial in our
model. Second, it is difficult to distinguish
between antibody-mediated rejection and ischthrough the recruitment of recipient neutrophils (22, 23). Simultaneemia-reperfusion injury clinically based on histologic features alone.
ously, donor nonclassical monocytes activate donor alveolar macroHistological features such as alveolar edema, neutrophil infiltration,
phages, which secrete monocyte chemoattractant protein-1, necesand capillaritis can be observed in both ischemia-reperfusion injusary for the mobilization of classical monocytes from the recipient
ry as well as antibody-mediated rejection, although the presence
spleen (18, 24). Upon migration to the transplanted lung allograft,
of complement deposition may favor the former (6, 40–43). Future
the recipient classical monocytes increase the pulmonary vasculaprospective studies, potentially including transcriptional profiling
ture permeability through the release of IL-1β, allowing the neutro(Figure 2), are necessary to distinguish pathological and molecular
phils to extravasate and initiate the pathogenesis of ischemia-reperfeatures to better characterize these disease states and enable delivfusion injury (24). We found that increased endothelial permeability
ery of therapies in the correct clinical context. Recently, exosomes
mediated by IL-1β was also necessary for the extravasation of LRAs
containing lung-restricted antigens have been detected during PGD
into the extravascular space and initiation of LRA-induced lung graft
in patients containing LRAs and could potentially be tested as a bioinjury. Nevertheless, LRAs caused lung injury even when donor
marker (44). Given the potential for complications associated with
nonclassical monocytes were depleted, which results in incomplete
severe immunosuppression, prophylactic use of complement inhibrecruitment of recipient classical monocytes (18, 24). This may sugitors in patients with LRAs is not scientifically justified. Instead, the
gest alternative sources of IL-1β production or the ability of even low
approach in our center is to use histology and complement staining,
levels of IL-1β to cause sufficient endothelial permeability to allow
when clinically feasible, to guide the use of complement inhibitors
LRA extravasation. Interestingly, administration of IL-1β into wild(45). Nevertheless, this should be prospectively validated in clinical
type naive mice induced extravasation of LRAs into the lung intertrials. Third, while we tested the known LRAs associated with PGD
stitium without activating complement (Figure 6). It is known that
in patients and causally linked to lung graft injury in animal models,
J Clin Invest. 2022;132(20):e157975 https://doi.org/10.1172/JCI157975
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Figure 4. LRAs activate classical and alternative complement pathways to mediate lung graft injury. (A) Diagram depicting experiments shown in B and C.
WT, C1q–/–, or Mbl–/– recipient mice received 150 μg each (i.v.) of isotype control or LRAs (anti–collagen type V plus anti–K-α1 tubulin) 24 hours before and 1 hour
after lung transplantation (Ltx). For some experiments, WT recipient mice treated with antibodies as described received C1INH, LNP023 (Factor B inhibitor,
FBI), or anti-C5 neutralizing antibody. (B) Arterial blood oxygenation from mice described in A was analyzed after clamping the right hilum (n = 3). (C) Quantification of neutrophil recruitment into lungs in mice treated as described in A (neutrophil gating: live CD45+SiglecF–CD11b+Ly6G+) (n = 3–5). (D and E) Immunocytochemistry for C4d (D) and C5b-9 (E) in allografts of LRA-treated mice (right) compared with isotype-treated mice (left). Data are presented as mean ± SD.
PaO2/FiO2, arterial oxygen pressure. Graphs were analyzed by 1-way ANOVA followed by Tukey’s post hoc test. *P < 0.05; ***P < 0.001; ****P < 0.0001; NS, not
significant. Scale bars: 20 μm and 10 μm (insets).

we acknowledge that it is unclear whether there are other immunogenic lung-specific antigens. Future studies incorporating contemporary techniques in proteomics and mass spectroscopy can potentially identify these proteins as well as their immunogenic epitopes.
Fourth, while only 2 patients developed features reminiscent of
antibody-mediated rejection, their response to treatment combined
with our preclinical data provides the foundation for a prospective
clinical trial. Fifth, while we found that neutrophils are recruited
during LRA-induced lung injury above the expected levels during
ischemia-reperfusion injury, the mechanisms remain unknown.
Donor nonclassical monocytes play a dominant role in recruiting host neutrophils through the secretion of chemokines and it is
possible that the LRA-antigen complex may enhance donor nonclassical monocytes by binding CD16.
In conclusion, we found that, in lung transplants, IL-1β increased
pulmonary endothelial permeability to allow the extravasation of
LRAs. Binding of LRAs to cognate self-antigens in the pulmonary
interstitium and ischemia-reperfusion caused the activation of
classical and alternative complement pathways, which contributed
6

to the immunopathogenesis of PGD, independent of neutrophilmediated ischemia-reperfusion injury. C5-inhibiting antibodies as
well as Factor B inhibition mitigated LRA-associated lung graft dysfunction in humans and mice.

Methods
Mice and procedures
Male wild-type C57BL/6J (B6), Fcrγ–/–, Il1r–/–, C1qa–/–, C3–/–, Mbl–/–, and
Nr4a–/– mice were obtained from The Jackson Laboratory. IL-1RA (0.2
ng/g body weight i.v.; Sigma-Aldrich) was used for IL-1β–IL-1R antagonism. C1INH (0.4 U/g body weight, Berinert, CSL Behring) and
LNP023 (Factor B inhibitor, 30 μg/g body weight, Adooq Bioscience)
were injected i.v. in recipients 24 hours before and 1 hour after lung
transplantation. IL-1β (10 μg/kg, i.v.; Thermo Fisher Scientific) was
injected 8 hours prior to LRA injection. Neutrophils were depleted by
using anti-Ly6G antibody (12.5 mg/kg body weight; Bio X Cell, clone
1A8). Complement C5 was inhibited by using a C5-blocking antibody
(100 μg/mouse, 1 hour before lung transplant; provided by Alexion
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Figure 5. LRA-induced lung dysfunction is complementary to ischemia-reperfusion injury. (A) Diagram depicting experiment shown in B and C. WT
recipient mice received 150 μg each (i.v.) of isotype control or LRAs (anti–collagen type V plus anti–K-α1 tubulin) 24 hours before and 1 hour after lung
transplantation (Ltx) using donor Nr4a1–/– mice. (B) Arterial blood oxygenation from mice described in A was analyzed after clamping the right hilum (n = 3).
(C) Quantification of neutrophil recruitment into lungs in mice treated as described in A (neutrophil gating: live CD45+SiglecF–CD11b+Ly6G+) (n = 3–4). (D) WT
recipient mice treated as in A were injected (i.p.) with isotype or anti-Ly6G antibody 24 hours before lung transplantation and harvested for determination
of pulmonary edema 24 hours after transplantation (n = 3). (E) WT recipient mice treated as described in D. Arterial blood oxygenation was analyzed after
clamping the right hilum (n = 3–4). Data are presented as mean ± SD. PaO2/FiO2, arterial oxygen pressure. Graphs were analyzed by 1-way ANOVA followed
by Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; NS, not significant.

Pharmaceuticals). Control mice were treated with the same amounts of
IgG isotype control antibody (Bio X Cell). All mice were maintained in a
specific pathogen–free facility at the Center for Comparative Medicine
at Northwestern University and used for the described experiments at
the age of 9–14 weeks and between 24 and 28 g of body weight.
Mouse lung transplant. Orthotropic murine left lung transplantation was performed as previously described (46). Briefly, donor mouse
was anesthetized with a mixture of xylazine (10 mg/kg) and ketamine
(100 mg/kg). Donor lungs were flushed through the pulmonary artery
with 3 mL of saline solution and the heart-lung block was excised and
kept in cooled (4°C) preservative solution. The bronchus, pulmonary
vein, and artery were dissected and prepared for anastomosis. A customized cuff made with a Teflon intravenous catheter was applied to
the vascular structures and fixated with a 10-0 nylon ligature. After
placement of a microvessel clip on the bronchus to avoid airway infiltration with preservative solution, the graft was stored at 4°C for a
period of 90 to 120 minutes of cold ischemic time prior to implantation. The recipient mouse received subcutaneous buprenorphine (0.1
mg/kg) 30 minutes prior to the thoracic surgical incision and every 6
hours as needed after the transplant procedure. The recipient mouse
was intubated and a left-sided thoracotomy was performed within the
third intercostal space. The recipient’s native lung was gently clamped
and pulled out of the thoracic cavity. The space between the artery,
the vein, and the bronchus was dissected separately. The artery and

vein were temporarily occluded using 8-0 nylon ligatures. The anastomoses were completed by fixating each cuff with 10-0 nylon ligatures.
The 8-0 ligatures were released (first vein, then artery) and the lung
inflated. The chest incision was closed and recipients separated from
the ventilator when spontaneous respiration resumed. No antibiotics
or immunosuppressive agents were used postoperatively in any group.
LRAs were administered i.v. in recipient mouse: 150 μg each (antiCOLV and anti-KAT) or 300 μg isotype rabbit IgG (Thermo Fisher Scientific) 24 hours before and 1 hour after lung transplantation.

Antibodies against KAT and COLV
Rabbit polyclonal IgG antibodies against KAT and COLV were produced
against KAT and COLV proteins as previously described (47). Purified
antibodies were endotoxin free by limulus amebocyte lysate assay.
F(ab′)2 fragments of IgG antibodies against KAT and COLV were prepared with a Pierce F(ab′)2 Preparation Kit, as described by the manufacturer (Thermo Fisher Scientific). For 2-photon microscopy, anti-COLV
antibody was conjugated to R-PE using a PE/R-Phycoerythrin Conjugation Kit - Lightning-Link (Abcam, ab102918).
Arterial blood gases
Arterial blood gases were measured using a fraction of inspired oxygen
of 100% after the right pulmonary hilum was clamped for 5 minutes (8).
Blood was collected by left ventricular puncture.
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Figure 6. IL-1β is necessary to increase vascular endothelial permeability and extravasation of LRAs. (A) Mouse primary lung microvascular endothelial
cells were seeded at 200,000 cells per insert and cultured until confluent. Monolayers were incubated for 24 hours in the absence (control, CT) or presence
of 50 ng/mL IL-1β in growth medium. FITC-antibody permeability testing was performed as described in the Methods. (B) Diagram depicting experiment
shown in C and D. WT recipient mice received 150 μg each (i.v.) of isotype control or LRAs (anti–collagen type V plus anti–K-α1 tubulin) 24 hours before and
1 hour after lung transplantation (Ltx). Donor lungs were from Il1r–/– mice or WT mice treated with IL-1RA 24 hours before and 1 hour after lung transplant.
(C) Arterial blood oxygenation from mice described in B was analyzed after clamping the right hilum (n = 3). (D) Quantification of neutrophil recruitment
into lungs in mice treated as described in B (neutrophil gating: live CD45+SiglecF–CD11b+Ly6G+) (n = 3–5). (E–G) Immunohistochemistry for C4d (E and G) and
LRAs (F) in allografts of LRA-treated wild-type mice (upper) compared with LRA-treated Il1r–/– mice (lower) (E) or in lungs from PBS- or IL-1β–treated mice
(F and G). Data are presented as mean ± SD. PaO2/FiO2, arterial oxygen pressure. Graphs were analyzed by 1-way ANOVA followed by Tukey’s post hoc test.
*P < 0.05; **P < 0.01; ***P < 0.001. Scale bars: 20 μm.

Wet to dry weight ratio
The transplanted left lung was harvested after reperfusion at defined
time points, weighed, and then placed at 54°C until a stable dry weight
was achieved. The ratio of wet weight to dry weight was then calculated as an indicator of pulmonary edema.
Flow cytometry
Mouse lung was digested and single-cell suspensions were prepared
as previously described (46). Cell suspensions underwent red blood
cell lysis using Pharm Lyse buffer (BD Biosciences). Live/dead staining was performed in protein-free solution (HBSS) using fixable viability dye eFluor 506 (eBioscience), followed by incubation with
FcR-blocking reagent (Miltenyi Biotec). Antibodies utilized for murine
cell staining included rat anti–mouse CD45–FITC (BioLegend,
30-F11), rat anti–mouse Ly6C–eFluor450 (eBiosciences, HK1.4), rat
anti–mouse I-A/I-E–PerCPCy5.5 (BioLegend, M5/114.15.2), rat anti–
mouse CD45–APC (BioLegend, 30-F11), rat anti–mouse Ly6G–Alexa
8

Fluor 700 (BioLegend, 1A8), rat anti–mouse NK1.1–Alexa Fluor 700
(BD, PK136), rat anti–mouse CD11b–APCCy7 (BioLegend, M1/70),
rat anti–mouse CD64–PE (BioLegend, X54-5/7.1), rat anti–mouse
SiglecF–PECF594 (BD, E50-2440), and rat anti–mouse CD11c–PECy7
(BD, HL3). For neutrophil quantification, 123Count eBeads (Invitrogen) were added. Flow analysis of fixed samples was done on a BD
FACSymphony A5-Laser Analyzer at the Northwestern University
Robert H. Lurie Comprehensive Cancer Center Flow Cytometry Core
facility. Acquired data were analyzed with FlowJo v10.8 (FlowJo).

Histology
Tissue sections were stained with hematoxylin and eosin and analyzed blindly. Images were obtained on a Nikon Eclipse microscope
or Olympus DP-71, and morphometric analysis was performed
using Nikon Elements software. Analysis was performed on 10 different areas of the lungs, and at least 10 high-powered fields were
analyzed in each area.
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Table 1. Characteristics of patients in study cohort
Variable
Age, years
Female
BMI, kg/m2
BSA, m2
Smoking history
Hypertension
Diabetes
CKD
Panel-reactive antibodies
Donor-specific antibodies

Overall (n = 56)

LRA (n = 8)

Non LRA (n = 48)

P value

59.5 ± 10.7
21 (37.5%)
25.8 ± 3.6
1.8 ± 0.2
33 (58.9%)
29 (51.7%)
19 (33.9%)
6 (10.7%)
12 (21.4%)
2 (3.5%)

61.0 ± 8.6
2 (25.0%)
27.3 ± 4.2
1.8 ± 0.1
4 (50.0%)
4 (50.0%)
2 (25.0%)
1 (12.5%)
3 (37.5%)
1 (12.5%)

59.3 ± 11.0
19 (43.1%)
25.2 ± 3.4
1.8 ± 0.2
29 (65.9%)
25 (56.8%)
17 (38.6%)
5 (11.3%)
9 (20.4%)
1 (2.7%)

0.69
0.69
0.18
0.81
0.90
0.82
0.71
0.91
0.34
0.26

11.9 ± 2.8
10.6 ± 4.7
223.7 ± 75.4
140.2 ± 2.2
16.0 ± 5.1
0.7 ± 0.1
19.5 ± 15.4
30.7 ± 20.3
5.1 ± 8.5
0.7 ± 0.6
1.1 ± 0.2

13.5 ± 3.0
11.9 ± 5.0
252.1 ± 81.9
140.0 ± 2.1
14.8 ± 3.0
0.8 ± 0.1
24.3 ± 28.0
33.0 ± 35.1
5.9 ± 2.8
0.7 ± 0.5
1.1 ± 0.2

11.6 ± 2.6
10.4 ± 4.6
218.8 ± 71.3
140.3 ± 2.2
16.1 ± 5.3
0.7 ± 0.1
18.7 ± 11.7
30.3 ± 16.4
3.9 ± 0.4
0.7 ± 0.6
1.1 ± 0.2

0.07
0.41
0.25
0.73
0.51
0.32
0.35
0.73
0.01
0.96
0.92

Laboratory
Hemoglobin, g/dL
WBC, 1,000/mm3
Platelets, 1,000/mm3
Sodium, mEq/L
BUN, mg/dL
Creatinine, mg/dL
ALT, U/L
AST, U/L
Albumin, g/dL
Total bilirubin, mg/dL
INR

package (48). Doublets were evaluated by scrublet
and removed (49). Downstream single-cell RNAseq analysis was performed using Seurat Package
version 4.0 following the standard workflow posted on the Satija lab website (https://satijalab.org/
seurat/) (50). Cells with unique feature counts less
than 200 or over 7500 were removed. Cells with
RNA counts less than 400 or over 40,000 were
removed. Cells having greater than 10% mitochondrial counts were removed. The data were
normalized by the “LogNormalize” method and
variable features were selected by “vst” method.
Reciprocal principal component analysis was used
for the data integration. Cell types were identified
using both manual annotations based on positive
markers from FindAllMarkers function in the
Seurat pipeline and a supervised annotation tool,
SingleR (51). The RNA-seq data can be found in
the NCBI Gene Expression Omnibus repository
(GEO GSE211501).

Two-photon intravital lung microscopy.
Two-photon intravital lung microscopy imaging
0.42
7.3 ± 0.1
7.3 ± 0.1
pH
7.3 ± 0.1
was performed using a Nikon A1R-MP+ multipho0.11
51.0 ± 12.0
43.7 ± 10.0
PaCO2
49.6 ± 12.0
ton microscope system with a Coherent Chame0.90
300.0 ± 109.0
306.2 ± 106.1
301.6 ± 108.3
PaO2
leon Vision titanium sapphire laser. As previously
0.11
28.5 ± 5.3
25.3 ± 3.7
28.0 ± 5.4
HCO3
described (18), mice were anesthetized with an i.p.
Donor
injection of ketamine (80 mg/kg) and xylazine (10
Age, years
34.5 ± 11.5
34.8 ± 11.5
34.4 ± 11.5
0.93
Female
23 (41.0%)
2 (25.0%)
21 (47.7%)
0.45
mg/kg), intubated orotracheally, and ventilated
Cause of death
with room air at a rate of 120 breaths/minute with
0.42
15 (31.2%)
4 (50.0%)
19 (33.9%)
Head trauma
a tidal volume of 0.5 mL. A left thoracotomy was
0.70
17 (35.4%)
2 (25.0%)
19 (33.9%)
Drug overdose
performed to expose the left lung, and the lung was
0.92
16 (33.3%)
2 (25.0%)
18 (32.1%)
Other
imaged using a custom-built chamber maintained
Continuous data are shown as mean ± SD. LRA, lung-restricted antibody; BMI, body mass index;
at 37°C. Vetbond was used to attach the lung tissue
BSA, body surface area; CKD, chronic kidney disease; WBC, white blood cell; BUN, blood urea
to the bottom of the cover glass without direct presnitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international
sure on the exposed lung. For time-lapse imaging
normalized ratio; ABG, arterial blood gas.
of location and extent of anti-COLV–PE deposition
in lungs, we averaged 37 video-rate frames (0.5 seconds per slice) during the acquisition to match the
ventilator rate and minimize movement artifacts.
Single-cell RNA-seq
To visualize blood vessels, 25 μL of FITC-dextran (2 × 106 Da, 5 mg/mL,
Single-cell suspensions from 24-hour posttransplant allografts from isoThermo Fisher Scientific) in 25 μL of PBS was injected i.v. 5 minutes pritype- or LRA-treated mice were prepared as described previously (18).
or to imaging. For each mouse, images of 512 × 512 μm in the x and y
Allograft was removed and digested with 3 mL Dispase (Corning) with
dimensions were acquired for 5 minutes prior to and for 15 minutes folDNase I (Sigma-Aldrich), and gently teased using forceps into small (1–2
lowing injection of anti-COLV–PE (1 mg/kg i.v.) using a water immersion
mm) fragments followed by incubation at room temperature with gentle
lens (Apo LWD 25× 1.10W DIC N2) at an excitation wavelength tuned
agitation for 30 minutes. The resulting suspension (in DMEM + 5% FBS)
at 1000 nm. Images were processed and analyzed using Nikon NIS-Elewas passed through a 70 μm cell strainer, erythrocytes were lysed, and filments NIS.ai and Bitplane Imaris software for background/fluorophore
tered through 40 μm cell strainers. Cells were counted using AO/PI and
spillover subtraction and fluorescence quantification of deposited fluoCellometer K2 (Nexcelom), and cell viability exceeded 90%. Single-cell
rophores. Data were transferred and plotted in GraphPad Prism 9.0 (Sun
3′ RNA-seq libraries were prepared using Chromium Single Cell V2
Microsystems) for analysis and creation of graphs.
Reagent Kit and Controller (10× Genomics). Libraries were assessed for
Bronchoalveolar lavage fluid
quality (TapeStation 4200, Agilent) and then sequenced on a NextSeq
The right pulmonary hilum was clamped, and left lung bronchoalveolar
500 or HiSeq 4000 instrument (Illumina). Initial data processing was
lavage fluid (BALF) was obtained by instilling lung airways 2 times with
performed using the Cell Ranger version 6.0 pipeline (10× Genomics),
0.5 mL PBS. BALF was centrifuged and the supernatant was used for
and reads were mapped to mm10 version of the mouse genome, Ensemcomplement C3 determination.
ble build 105. Ambient RNA contamination was removed by the SoupX

ABG (at cannulation)
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Table 2. Multivariate logistic regression analysis: predictors of
postoperative primary graft dysfunction
Variable

OR

P value

95% CI

LRA

15.00

0.04

1.12–202.0

Platelets, 1,000/mm3
Total bilirubin, mg/dL

0.95
1.57

0.13
0.53

0.96–1.01
0.37–6.53

Laboratory

LRA, lung-restricted antibody.

ELISA
Mouse complement C3 ELISAs were performed using commercially
available kits accordingly to the manufacturer’s instructions (Abcam).
To determine autoantibodies in patients’ serum, LABScreen autoantibody kits (LSAUT1-3, One Lambda) was used according to the manufacturer’s instructions.
Immunohistochemistry
Mice were anesthetized with pentobarbital sodium (50 mg/kg, i.p.)
and lung tissues were excised and fixed with 10% neutral buffered
formalin. Paraffin-embedded sections were incubated with rabbit
anti-C4d IgG (1:200, overnight at 4°C; Hycult Biotech, HP8033) or
rabbit anti–C5b-9 IgG (Bioss Antibodies, bs-2673R) and then successively reacted with donkey anti–rabbit IgG H&L (Alexa Fluor 488)
(1:500, 1 hour at room temperature; Abcam, ab150073). For LRA
deposition, paraffin-embedded sections were incubated directly with
with donkey anti–rabbit IgG H&L (Alexa Fluor 488) as above. Nuclei
were stained with Hoechst 33342 (MilliporeSigma). Confocal images
were acquired using a Zeiss Axio Imager Z2 with ApoTome.2 microscope equipped with Axiocam 503 Mono, X-Cite 120 LED Boost System and Zen 2.3 software (Carl Zeiss).
In vitro endothelial cell permeability
Lung primary microvascular endothelial cells (Cell Biologics, C576011) were grown in phenol red–free endothelial cell medium (ScienCell), seeded in collagen-coated inserts, and permeability was
determined using a vascular permeability assay kit according to the
manufacturer’s instructions (Millipore). FITC-conjugated anti-COLV
antibody, labeled using a FITC Conjugation Kit (Fast) - Lightning-Link
(Abcam), was added to wells in the absence or presence of 50 ng/mL
recombinant mouse IL-1β (Thermo Fisher Scientific) and fluorescence
was red with a plate reader with filters appropriate for 485 nm and 535
nm excitation and emission, respectively.
Definition of primary graft dysfunction
Patients with no evidence of pulmonary edema on chest x-ray were
considered grade 0. Absence of invasive mechanical ventilation was
graded according to the PaO2/FiO2 ratio, using methods similar to
those receiving mechanical ventilation. If PaO2 was not available for
calculation of a PaO2/FiO2 ratio, then an oxygen saturation/FiO2 ratio
was used for calculations. Grade 3: PaO2/FiO2 ratio < 200. The worst
PaO2/FiO2 ratio within 72 hours after lung transplantation was used.
Use of extracorporeal lung support with bilateral pulmonary edema
on chest x-ray image was considered grade 3.
10

Immunosuppressive therapy
All lung transplant recipients received standardized immunosuppressive therapy. Methylprednisolone 500 mg i.v. intraoperatively and
basiliximab 20 mg i.v. intraoperatively and postoperative day (POD) 4
were given as induction immunosuppressive therapy.
Maintenance immunosuppression was conducted as follows:
Prednisone 0.5 mg/kg p.o. daily from POD 1, mycophenolate mofetil
1000 mg i.v. bid from POD 1, and tacrolimus 0.015 mg/kg total daily
dose sublingual, targeting from 8 to 12 ng/mL.
Patients with LRAs that developed PGD underwent treatment for
antibody-mediated rejection using i.v. methylprednisolone (1000 mg)
for 3 days, and daily plasmapheresis for 3 days followed by i.v. immunoglobulin (1 mg/kg) and eculizumab (1200 mg, 900 mg, and 600
mg on days 1, 2, and 3).
Statistics
Murine. Mouse data analysis was performed using Prism 8 (GraphPad
Software). Results are expressed as mean ± SD and the n values for each
data set are provided in the figure legends. Statistical significance was
assessed by 2-tailed Student’s t test or 1-way ANOVA followed by Tukey’s
post hoc test. A P value of less than 0.05 was considered significant.
Human. Incidence of grade 3 primary graft dysfunction after
lung transplantation was compared between the LRA-positive and
LRA-negative groups. Continuous variables were compared using a
2-tailed Student’s t test and are reported as mean ± SD. Categorical
variables were compared using Fisher’s exact test and are reported
as numbers (percentages). P values of less than 0.05 were accepted as statistically significant. A logistic regression model was used
to derive odds ratios and 95% CIs. To build our models, we performed a univariate analysis and included all predictors if the test
had a P value of 0.2 or less. To assess the overall goodness of fit, we
used Gronnesby’s and Borgan’s tests. Statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R
Foundation for Statistical Computing, Vienna, Austria). It is a modified version of R commander designed to add statistical functions
frequently used in biostatistics.
Study approval
Murine. All procedures were approved by the Institutional Animal
Care and Use Committee (IS00010493) at Northwestern University.
Animals received humane care in compliance with the NIH Guide for
the Care and Use of Laboratory Animals (National Academies Press,
2011) and the Principles of Laboratory Animal Care formulated by
the National Society for Medical Research.
Human. Patient data were collected retrospectively using the electronic medical records and stored in a database. A total of 56 adult
patients undergoing lung transplantation at our institution were prospectively tested for antibodies. This study was approved by The Northwestern University Institutional Review Board (STU00207250). However, the need for patient consent for data collection was waived by the
IRB as this was a retrospective study.
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